By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Kite Pharma, Inc. 

2225 Colorado Avenue

Santa Monica  California  90404  U.S.A.
Phone: 301-824-9999 Fax: n/a


Company News
Kite Pharma (KITE) Presents Promising Preclinical Data From KITE-585, A Fully Human Anti-BCMA CAR T-Cell Product Candidate At The 2017 AACR Annual Meeting 4/5/2017 8:23:16 AM
Kite Pharma (KITE) Highlights Publication On Breakthrough In Generating Fully Functioning T Cells From Hematopoietic Precursor Cells By Leading Researchers At UCLA 4/4/2017 7:01:40 AM
Kite Pharma (KITE) Presents Ongoing Response Rate In Plenary Session From Its Pivotal CAR-T Trial Of Axicabtagene Ciloleucel In Patients With Aggressive Non-Hodgkin Lymphoma At The 2017 AACRh Annual Meeting 4/3/2017 2:27:33 PM
Novartis AG (NVS) Looks Over Its Shoulder as Kite Pharma (KITE) Hits Its BLA Filing Deadline 4/3/2017 6:15:00 AM
Kite Pharma (KITE) To Present Two Plenary Presentations From The ZUMA-1 Pivotal Trial Of Axicabtagene Ciloleucel At The 2017 AACR Annual Meeting 3/30/2017 8:11:00 AM
Kite Pharma (KITE) Announces Appointment Of Renowned Cancer Researcher, Owen N. Witte, M.D., To Its Board Of Directors 3/16/2017 8:51:37 AM
Kite Pharma (KITE) Highlights Publication From NCI Demonstrating Durable Complete Remissions In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy And Anti-CD19 CAR T-Cell Therapy 3/15/2017 8:09:36 AM
Kite Pharma (KITE) Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares 3/8/2017 8:07:33 AM
Kite Pharma (KITE) Release: Richard L. Wang Named Chief Executive Officer Of Fosun Kite Biotechnology Co., Ltd., A Joint Venture To Lead Development Of Axicabtagene Ciloleucel And Other Engineered T-Cell Therapies For Treatment Of Cancers In China 3/6/2017 6:48:33 AM
Kite Pharma (KITE) Announces Commencement Of Public Offering Of Common Stock 3/2/2017 8:16:15 AM